A Trial in Healthy Female Subjects to Compare the Pharmacokinetics of Ethinyl Estradiol of NuvaRing®, a Contraceptive Patch (EVRA(TM)) and an Oral Contraceptive (Microgynon® 30) (Study 34237 (P06650)) (COMPLETED)

NCT ID: NCT01044056

Last Updated: 2022-02-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2004-03-31
• Study Completion Date: 2004-06-30

Brief Summary

An open-label, randomized, parallel group trial in healthy female subjects to compare the pharmacokinetics of ethinyl estradiol (EE) of NuvaRing®, a contraceptive patch (EVRA(TM)) and an oral contraceptive (Microgynon® 30).

Conditions

Contraception

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Levonorgestrel/ethinylestradiol oral contraceptive pill

Microgynon(R), 1 tablet every day for 21 days; each tablet contains 0.150 mg levonorgestrel (LNG) and 0.030 mg ethinylestradiol (EE).

Group Type: ACTIVE_COMPARATOR

Levonorgestrel (LNG)/Ethinylestradiol (EE) oral contraceptive tablets

Intervention Type: DRUG

LNG/EE oral contraceptive tablets (Microgynon® 30), 21 in total, containing 0.150 mg LNG and 0.030 mg EE per tablet administered once daily orally for 21 consecutive days.

Norelgestrominum and ethinylestradiol contraceptive patch

Evra(TM), One patch applied on lower abdomen for 7 days for 3 consecutive weeks, 3 patches in total. Each patch contains 6 mg norelgestromin and 0.750 mg EE releasing 0.150 mg norelgestromin and 0.020 mg EE per day.

Group Type: ACTIVE_COMPARATOR

norelgestrominum and ethinylestradiol patch oral contraceptive patch

Intervention Type: DRUG

A contraceptive patch (EVRA ™), one patch for 7 days for three consecutive weeks, 3 patches in total, applied on the lower abdomen. Dose: per patch 6 mg norelgestromin and 0.750 mg EE releasing 0.150 mg norelgestromin and 0.020 mg EE per day.

Etonogestrel and ethinylestradiol contraceptive vaginal ring

Nuvaring(R), Place the ring in the vagina for 21 days, remove for one week. Repeat with new Ring. Dose: per ring 11.7 mg ENG and 2.7 mg EE releasing a daily average amount of 0.120 mg ENG and 0.015 mg EE.

Group Type: ACTIVE_COMPARATOR

Nuvaring ™ (etonorgestrel/ethinylestradiol)

Intervention Type: DRUG

NuvaRing ™ , one ring for a period of 21 days, inserted vaginally. Dose: per ring 11.7 mg etonogestrel and 2.7 mg EE releasing a daily average amount of 0.120 mg etonogestrel and 0.015 mg EE.

Interventions

Levonorgestrel (LNG)/Ethinylestradiol (EE) oral contraceptive tablets

LNG/EE oral contraceptive tablets (Microgynon® 30), 21 in total, containing 0.150 mg LNG and 0.030 mg EE per tablet administered once daily orally for 21 consecutive days.

Intervention Type: DRUG

norelgestrominum and ethinylestradiol patch oral contraceptive patch

A contraceptive patch (EVRA ™), one patch for 7 days for three consecutive weeks, 3 patches in total, applied on the lower abdomen. Dose: per patch 6 mg norelgestromin and 0.750 mg EE releasing 0.150 mg norelgestromin and 0.020 mg EE per day.

Intervention Type: DRUG

Nuvaring ™ (etonorgestrel/ethinylestradiol)

NuvaRing ™ , one ring for a period of 21 days, inserted vaginally. Dose: per ring 11.7 mg etonogestrel and 2.7 mg EE releasing a daily average amount of 0.120 mg etonogestrel and 0.015 mg EE.

Intervention Type: DRUG

Other Intervention Names

Microgynon; Batch Number: 374A 01K05; EVRA ™; Batch number : 0311264

Eligibility Criteria

Inclusion Criteria

• Subject is at least 18 but not older than 40 years of age on Day 1 of treatment.
• Subject has uterus and ovaria in situ
• Subject who does not use hormonal contraception and is willing to use adequate nonhormonal contraceptive measures during the timeframe between screening and start treatment.
• Subject is able and willing to refrain from caffeine and/or xanthine containing food and/or beverages (e.g. coffee, tea, cola or chocolate) from 24 hours before the first administration of the trial medication until the last PK blood sample.
• Subject is willing not to consume grapefruit containing products 14 days prior to the start of the first administration of the trial medication until the last PK blood sample.
• Subject is willing to refrain from smoking from 7 days prior to first administration of the trial medication until the last pharmacokinetic blood sample.
• Subject is willing to refrain from alcohol containing products from 24 hours prior to first administration of the trial medication until the last pharmacokinetic blood sample.

Exclusion Criteria

• Contraindications for use of NuvaRing, contraceptive patch and oral contraceptive:
• Presence or history of venous thrombosis, with or without the involvement of pulmonary embolism.
• Presence or history of arterial thrombosis (e.g. cerebrovascular accident, myocardial infarction) or prodromi of a thrombosis (e.g. angina pectoris or transient ischaemic attack).
• Known predisposition for venous or arterial thrombosis, with or without hereditary involvement such as Activated Protein C (APC) resistance, antithrombin-III deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinaemia, antiphospholipid antibodies (anticardiolipin antibodies, lupus anticoagulant) and Factor V Leiden mutation.
• Diabetes mellitus with vascular involvement
• The presence of a severe or multiple risk factor(s) for venous or arterial thrombosis (to be judged by the (sub-) investigator
• Presence or history of severe hepatic disease as long as liver function values had not returned to normal or were judged to be clinically significant by the investigator.
• Presence or history of liver tumours (benign or malignant).
• Known or suspected malignant conditions of the genital organs or the breasts, if sex-steroid-influenced.
• Undiagnosed vaginal bleeding.
• Hypersensitivity to the active substances or to any of the excipients of NuvaRing, contraceptive patch and oral contraceptive.
• Migraine with focal aura
• Known or suspected pregnancy
• Breastfeeding, or within 2 months after stopping breastfeeding on the day preceding the first administration of trial medication (Day -1).
• Clinically significant abnormal laboratory, ECG (electrocardiogram) vital signs, physical and gynecological findings at screening.
• A significant (history of) allergic or other serious disease, particularly gastrointestinal tract disease.
• Smoking more than 5 cigarettes or 1 pipe or 1 cigar per day for a period of at least 3 months prior to screening.
• Using any systemic medication (including over the counter (OTC) medication) during the 14 days prior to the day preceding the first administration of trial medication (Day -1), except for oral contraceptive used for synchronization and occasional Ibuprofen.
• Used any drug or substance that is known to induce drug-metabolizing enzymes within two months prior to the start of synchronization.
• Received a contraceptive by injection, an implant or hormonal intra-uterine device within 6 months of the day preceding the first administration of trial medication (Day -1), or a hormonal implant or hormonal intra-uterine device removed within 6 months of the day preceding the first administration of trial medication (Day -1).
• Participated in a drug trial and was administered an investigational drug during the 90 days prior to start of synchronization.
• Donated blood during the 90 days prior to the day preceding the first administration of trial medication (Day -1).
• History (within the last 2 years) of excessive alcohol use, use of solvents or of drug abuse.
• Positive drug test at screening and/or admission (Day -1), or a positive alcohol test at admission (Day -1).
• Clinically significant abnormal cervical smear result (papaninecolaou (PAP) III or higher) at screening.
• Acute or chronic hepatitis B/C or human immune deficiency virus (HIV) 1&2 infection.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Organon and Co

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

References

van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception. 2005 Sep;72(3):168-74. doi: 10.1016/j.contraception.2005.03.005.

Reference Type: RESULT

PMID: 16102549 (View on PubMed)

Other Identifiers

P06650

Identifier Type: -

Identifier Source: org_study_id